Stockscreener 앱 받기
363.96
0.68%
2.615
전일 마감가:
$361.35
열려 있는:
$361.55
하루 거래량:
312.21K
Relative Volume:
0.23
시가총액:
$48.08B
수익:
$3.21B
순이익/손실:
$43.57M
주가수익비율:
1,513.37
EPS:
0.2405
순현금흐름:
$221.36M
1주 성능:
+2.33%
1개월 성능:
-9.18%
6개월 성능:
+10.64%
1년 성능:
+31.47%
1일 변동 폭
$361.55
$368.07
1주일 범위
$351.55
$376.87
52주 변동 폭
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
363.94 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.30 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.84 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
878.06 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
336.48 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | Oppenheimer | Outperform |
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression - Insider Monkey
EFG Asset Management North America Corp. Trims Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
The Five Minute Read - lowellsun.com
Mitsubishi UFJ Trust & Banking Corp Sells 8,273 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2026 Revenue Guidance Signals Strong Growth Potential - simplywall.st
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Popularity With Investors Is Under Threat From Overpricing - 富途牛牛
Jennison Associates LLC Has $139.02 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Baillie Gifford & Co. Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Should Alnylam’s Aggressive 2026 Revenue Guidance Reframe the Risk‑Reward for Alnylam Pharmaceuticals (ALNY) Investors? - simplywall.st
31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat
Nanomedicine Market Reached USD 169.51 Billion in 2024, to Reach - openPR.com
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million - MSN
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Technical Reactions to ALNY Trends in Macro Strategies - Stock Traders Daily
RBC Capital Maintains Rating but Lowers Alnylam Pharmaceuticals (ALNY) Price Target | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $376.00 Price Target at Wells Fargo & Company - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $465.00 at Royal Bank Of Canada - MarketBeat
356,529 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Allstate Corp Acquires Shares of 4,571 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Price Action: What analysts say about Alnylam Pharmaceuticals Inc stockWeekly Investment Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
Donoghue Forlines LLC Takes $2.11 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Growth in Short Interest - MarketBeat
Aug Volume: How does Alnylam Pharmaceuticals Inc perform in inflationary periodsJuly 2025 Opening Moves & Stock Portfolio Risk Management - baoquankhu1.vn
Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After Recent RNAi Pipeline Progress? - simplywall.st
Wolverine Asset Management LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Campbell & CO Investment Adviser LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A Look Into Alnylam Pharmaceuticals Inc's Price Over Earnings - Sahm
Insider Selling: Jeffrey V Poulton Unloads $1.01M Of Alnylam Pharmaceuticals Stock - Benzinga
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
How Does Geopolitics Affect the Life Sciences Industry? 3 Executives Weigh In - MedCity News
Alnylam EVP Pushkal Garg sells $547k in stock By Investing.com - Investing.com South Africa
Alnylam EVP Pushkal Garg sells $547k in stock - Investing.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,008,778.60 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 9,577 Shares - MarketBeat
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 1,510 Shares of Stock - MarketBeat
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 2,290 Shares of Stock - MarketBeat
JPM preannouncements: Why Alnylam and Sarepta lost, but Day One won - MSN
Is It Time To Reassess Alnylam (ALNY) After Recent Share Price Pullback? - Yahoo Finance
JPM26: 2025 a “breakout year” for rare disease biotechs - Yahoo Finance
Aug Gainers: What is ORLYs book value per shareQuarterly Profit Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal - Yahoo Finance
Market Review: What dividend safety score for Alnylam Pharmaceuticals Inc stockIndex Update & Reliable Intraday Trade Alerts - moha.gov.vn
H.C. Wainwright reiterates Buy rating on Alnylam stock with $570 price target - Investing.com UK
Tokio Marine Asset Management Co. Ltd. Takes $2.03 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Sumitomo Mitsui Trust Group Inc. Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals CEO on Development Goals, Profitability - marketscreener.com
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY - TechStock²
JPM preannouncements take their toll as Alnylam slides, Tempus, Day One pop - MSN
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Jan 12 '26 |
Sale |
362.86 |
9,577 |
3,475,157 |
78,411 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Jan 12 '26 |
Sale |
362.87 |
2,780 |
1,008,766 |
57,465 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Jan 12 '26 |
Sale |
362.87 |
1,510 |
547,927 |
29,728 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Jan 13 '26 |
Sale |
370.33 |
2,290 |
848,065 |
21,264 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Jan 12 '26 |
Sale |
362.87 |
1,510 |
547,927 |
23,554 |
5.37%
0.51%
자본화:
|
볼륨(24시간):